Auranofin
Auranofin
Definition
An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis.
Also known as AURANOFIN, Ridaura — per NCIT
Also identified as
- ATC M01CB03 per RXNORM
- NCIT NCIT:C65242 per NCIT
- SCTID 18002004 per RXNORM
- SCTID 387100001 per RXNORM
- UNII 3H04W2810V per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Pemphigus | may treat | MEDRT · Public domain (U.S. Government work) |
| Psoriatic arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
| Rheumatoid arthritis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone element | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Musculoskeletal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skeletal joint | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Skin of body | may treat a disease of this organ | DERIVED · CC BY 4.0 |
4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.